Welcome to our dedicated page for Psyence Biomedical Ltd. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence Biomedical Ltd. is consolidating its common shares through a 1-for-6.25 reverse stock split. The company now expects its shares to begin trading on a post-consolidated basis at the opening of the market on February 2, 2026.
At the effective time, every 6.25 issued and outstanding common shares will be combined into one share, and the number of shares underlying outstanding warrants and other equity instruments and their exercise prices will be adjusted proportionately under their terms. As of January 21, 2026, Psyence BioMed had 6,388,604 common shares issued and outstanding; following the consolidation it will have 1,022,177 common shares issued and outstanding.
The reverse split is intended, among other things, to support the company’s ability to maintain compliance with Nasdaq continued listing standards. The consolidation applies uniformly to all shareholders, with only minor differences from rounding of fractional shares. Continental Stock Transfer & Trust Company will act as exchange and transfer agent, and most shareholders will not need to take action.
Psyence Biomedical Ltd. filed a report explaining that its annual and special shareholder meeting, originally set for January 22, 2026, was adjourned because not enough shares were represented to reach quorum. The meeting has been rescheduled to February 12, 2026 at 9:00 a.m. New York time / 4:00 p.m. Cape Town time in Cape Town, South Africa, and the record date for voting remains December 23, 2025. The company is working with its proxy agents to obtain sufficient shareholder participation and notes that there is no assurance quorum will be reached, highlighting potential delays or challenges around completing the planned meeting business.
Psyence BioMed Ltd. is implementing a 1-for-6.25 reverse stock split of its common shares. Every 6.25 issued and outstanding shares will be combined into one share, and the change is expected to take effect for trading at the market open on January 20, 2026. The shares will continue to trade on the Nasdaq Capital Market under the symbol PBM with a new CUSIP number 74449F407.
As of January 14, 2026, the Company had 6,388,604 common shares issued and outstanding, which will become 1,022,177 common shares after the consolidation. The exercise prices and number of shares underlying warrants and other equity instruments will be adjusted proportionately. No fractional shares will be issued; positions will be rounded up or down to the nearest whole share. The Company states that the consolidation is expected to support its continued compliance with Nasdaq’s listing standards, although risks such as potential share price volatility and regulatory challenges remain.
KAOS Capital Ltd. and founder Adam Arviv filed Amendment No. 1 to their Schedule 13D on Psyence Biomedical Ltd., reporting beneficial ownership of 313,876 common shares, or 4.91% of the company’s outstanding stock. The filing notes they used approximately $519,493.36 of KAOS working capital to acquire these shares. The investors state they view Psyence as an attractive opportunity but express significant concerns about how the company’s assets are currently managed. They intend to engage with management and the board on operations, governance, strategy, and possible alternative directors and strategic changes. Because their ownership fell below five percent due to changes in shares outstanding, this amendment is described as their final Schedule 13D amendment for Psyence.
Psyence Biomedical Ltd. approved a 2026 financial strategy and capital management framework that includes a Board-authorized share repurchase program the company may use when it sees a value opportunity. The Board believes the current market price may not reflect the underlying value of the common shares, so buybacks, if executed, could increase remaining shareholders’ per-share ownership if the repurchased shares are cancelled. Any repurchases would be optional, conducted through an independent broker, and subject to liquidity, valuation, regulatory and market conditions, as well as maintaining an appropriate cash runway for planned clinical and regulatory milestones. The program can be implemented over the next six to twelve months but may be modified, suspended or terminated at any time, and there is no obligation to repurchase any shares.
Psyence Biomedical Ltd. filed an amendment to a prior Form 6-K to replace its Notice of Meeting and Form of Proxy exhibits. The updated notice calls an annual and special shareholder meeting to be held in person in Cape Town on January 22, 2026 at 9:00 a.m. New York time.
Shareholders will be asked to receive the audited financial statements for the year ended March 31, 2025 and interim statements for the six months ended September 30, 2025, appoint MNP LLP as auditor and authorize the directors to set audit fees, elect directors, and approve a special resolution for a consolidation of the company’s common shares. Shareholders wishing to vote by proxy must submit their forms by 11:59 p.m. New York time on January 21, 2026.
Psyence Biomedical Ltd. has called an annual and special shareholder meeting for January 22, 2026 in Cape Town. Shareholders will review audited financial statements for the years ended March 31, 2025 and 2024 and interim results for the six months ended September 30, 2025, appoint MNP LLP as auditor, and elect five directors.
A key item is a special resolution authorizing the board to complete one or more consolidations of the company’s common shares at a ratio of up to 250 pre-consolidation shares for one post-consolidation share, at the board’s discretion before the next annual meeting. At a 250:1 ratio, the current 6,388,604 common shares would become approximately 25,554 shares, with fractional shares rounded up or down.
The circular also describes the 2023 Equity Incentive Plan, which includes options, restricted shares and restricted share units with evergreen share increase features, and provides detailed disclosure on board composition, committee structure, director independence and executive and director compensation arrangements.
Psyence Biomedical Ltd. (PBM) filed a prospectus supplement that incorporates its latest Form 6-K, providing unaudited results for the three and six months ended September 30, 2025. PBM is a Nasdaq-listed biotech developing nature-derived psilocybin and ibogaine therapies, with its lead candidate PEX010 in an 87-patient Phase IIb palliative care study in Australia, where multiple patients have been enrolled and dosed.
For the six months ended September 30, 2025, PBM recorded a net loss of $1,992,732, compared with net income of $2,960,655 in the prior-year period, when results were boosted by large fair value gains on financial instruments. Operating expenses shifted: sales and marketing fell to $154,976 from $320,708 and general and administrative costs declined to $367,070 from $536,140, while research and development rose to $672,364 as clinical activity increased and professional and consulting fees grew to $1,223,637 due to higher legal and advisory work.
PBM strengthened its balance sheet through its equity line of credit, issuing 1,283,950 shares for total consideration of $7,349,396 and ending the period with cash and restricted cash of $7,197,176 and working capital of $6,686,387. The company invested $4,000,000 in Psyence Labs Ltd. and marked this stake at a fair value of $5,172,000, recognizing a $427,000 unrealized gain. Management notes ongoing cash outflows and emphasizes that continued funding will be required to support research, clinical trials and operations.
Psyence Biomedical Ltd. submitted a Form 6-K to provide investors with its unaudited condensed consolidated financial statements and management’s discussion and analysis for the three and six months ended September 30, 2025 and 2024. These documents give updated insight into the company’s recent operating and financial performance between formal annual reports.